These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21707498)

  • 21. Epothilone B induces glioblastoma cell death via survivin down-regulation.
    Quick QA
    Exp Oncol; 2008 Sep; 30(3):195-201. PubMed ID: 18806741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
    Cam M; Charan M; Welker AM; Dravid P; Studebaker AW; Leonard JR; Pierson CR; Nakano I; Beattie CE; Hwang EI; Kambhampati M; Nazarian J; Finlay JL; Cam H
    Neuro Oncol; 2020 Mar; 22(3):345-356. PubMed ID: 31763674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype.
    Wilson L; Lopus M; Miller HP; Azarenko O; Riffle S; Smith JA; Jordan MA
    Biochemistry; 2015 Oct; 54(42):6482-9. PubMed ID: 26435331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel delivery strategies for glioblastoma.
    Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
    Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule.
    Das SK; Sarkar D; Cavenee WK; Emdad L; Fisher PB
    ACS Chem Neurosci; 2019 Mar; 10(3):1121-1123. PubMed ID: 30681320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.
    Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ
    J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. βIII-Tubulin: biomarker of taxane resistance or drug target?
    Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
    Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleic acid-based therapeutics for glioblastoma.
    Shir A; Levitzki A; Wagner E; Klein S; Ogris M
    Anticancer Agents Med Chem; 2011 Oct; 11(8):693-9. PubMed ID: 21707501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
    Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
    Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of octamer binding transcription factors in glioblastoma multiforme.
    Rooj AK; Bronisz A; Godlewski J
    Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
    Nana AW; Yang PM; Lin HY
    Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
    Zhao J; Zhang B; Shen S; Chen J; Zhang Q; Jiang X; Pang Z
    J Colloid Interface Sci; 2015 Jul; 450():396-403. PubMed ID: 25863222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
    Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
    Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiogenesis in glioblastoma multiforme: navigating the maze.
    Linkous AG; Yazlovitskaya EM
    Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.